Research & Clinical Trials

Interpreting Peptide Research Studies

Learn how to critically evaluate peptide research, including study design, statistical significance, and common limitations.

Literature Review · October 11, 2026 · 8 min read

Most claims about research peptides trace back to a real study. The study is usually real; the claim is usually bigger than the study supports. Closing that gap is a skill worth having.

Start with the species

This single question resolves most peptide claims. A striking proportion of what circulates about BPC-157, TB-500, MOTS-c and epithalon comes from rodent studies.

Animal results are not worthless; they are how drug development begins. But the attrition rate from promising animal data to working human medicine is brutal, and "healed tendons in rats" is a hypothesis about humans, not a finding.

Then ask who ran it, and who else has

Independent replication is what turns a result into knowledge. Several popular research peptides have an evidence base dominated by one group publishing repeatedly over years. That pattern is not evidence of dishonesty, but it is a weaker foundation than the same finding reproduced by unconnected labs.

Check what was actually measured

Studies often measure a proxy because the real outcome is slow or expensive to observe. Raising a biomarker is easier to demonstrate than improving health.

  • NAD+ precursor trials reliably show raised blood NAD+ levels. Whether that translates into any health benefit is far less settled.
  • Epithalon research reports increased telomerase activity in cell cultures. Telomerase activity is not longevity.
  • CJC-1295 studies confirmed raised growth hormone and IGF-1. Neither was shown to improve anything.

Size, duration and statistics

Small studies produce unstable results, and a p-value below 0.05 means the result would be uncommon if there were no real effect, not that the effect is large or important. Always look for the effect size alongside the significance.

Duration matters for anything taken long-term. The longest retatrutide data runs about two years. That is substantial for a trial and short for a medicine someone might take for decades.

Watch for the citation that does not say what it is cited for

A recurring pattern in peptide marketing is a real citation attached to a claim the paper never made. Papers about the parent protein get cited for the fragment sold online. Papers about a topical formulation get cited for an injection.

If a claim matters to you, open the source. The abstract alone will usually tell you the species, the number of participants and the actual outcome measured.

Content is provided for educational purposes only and does not constitute medical advice. Investigational compounds may lack established human safety, efficacy, and dosing information.